Cargando…
Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities
RATIONALE: Concern for immune-related adverse events from immunotherapy and radiation therapy are well-documented; however, side effects are mostly mild to moderate. However, high-grade, potentially life-threatening adverse events are increasing. While case reports regarding immunotherapy-related bu...
Autores principales: | Huynh, Linda My, Bonebrake, Benjamin T., DiMaio, Dominick J., Baine, Michael J., Teply, Benjamin A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8663808/ https://www.ncbi.nlm.nih.gov/pubmed/34889301 http://dx.doi.org/10.1097/MD.0000000000028199 |
Ejemplares similares
-
Development of bullous pemphigoid during nivolumab therapy
por: Damsky, William, et al.
Publicado: (2016) -
Delayed Onset of Bullous Pemphigoid Secondary to Nivolumab
por: Olsen, Eric, et al.
Publicado: (2023) -
A Case of Bullous Pemphigoid Associated With Nivolumab Therapy
por: Gotera, Nico, et al.
Publicado: (2022) -
Nivolumab-Induced Bullous Pemphigoid Managed without Drug Withdrawal
por: Munera-Campos, Mónica, et al.
Publicado: (2020) -
Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab
por: Mizutani, Kosuke, et al.
Publicado: (2021)